Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-therapy for Acute Schizophrenic

Study identifier:D1443L00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 24-week, Multi-Centre, Open-label, Single-Arm, Phase IV Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) with Daily Dose 600mg-750mg as Mono-therapy in the Treatment of Acute Schizophrenic Patients

Medical condition

schizophrenia

Phase

Phase 4

Healthy volunteers

No

Study drug

Quetiapine Fumarate (Seroquel)

Sex

All

Actual Enrollment

120

Study type

Interventional

Age

18 Years - 60 Years

Date

Study Start Date: 01 Dec 2006
Primary Completion Date: 01 Sept 2007
Study Completion Date: 01 Sept 2007

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria